Alpha Cognition Inc. (OTC:ACOGF – Get Rating) – Stock analysts at Zacks Small Cap lifted their FY2023 earnings estimates for Alpha Cognition in a research report issued on Wednesday, March 15th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings of ($0.09) per share for the year, up from their prior estimate of ($0.17). The consensus estimate for Alpha Cognition's current full-year earnings is ($0.17) per share.
Get
Alpha Cognition alerts:
Separately, Raymond James cut shares of Alpha Cognition from an "outperform" rating to a "market perform" rating in a report on Friday, February 10th.
Alpha Cognition Price Performance
Shares of Alpha Cognition stock opened at C$0.30 on Friday. The firm has a market cap of C$18.30 million, a price-to-earnings ratio of -1.67 and a beta of 2.92. The stock has a 50-day simple moving average of C$0.27 and a 200-day simple moving average of C$0.30. Alpha Cognition has a 52-week low of C$0.15 and a 52-week high of C$1.08.
About Alpha Cognition
(Get Rating)
Alpha Cognition Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS.
Featured Stories
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don't Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
Alpha Cognition Inc.(場外交易代碼:ACOGF-GET Rating)-在3月15日星期三發佈的一份研究報告中,ZacksSmall Cap的股票分析師上調了對Alpha Cognition 2023財年的收益預期。Zack Small Cap分析師J·範德莫斯滕現在預測,該公司今年的每股收益將為0.09美元,高於此前預測的0.17美元。對Alpha Cognition目前全年收益的普遍估計是每股0.17美元。
到達
阿爾法認知警報:
另外,雷蒙德·詹姆斯在2月10日星期五的一份報告中將Alpha Cognition的股票評級從“跑贏大盤”下調至“市場表現”。
阿爾法認知價格表現
週五,Alpha Cognition的股票開盤報0.30加元。該公司市值為1830萬加元,本益比為-1.67倍,貝塔係數為2.92。該股的50日簡單移動均線切入位在0.27加元,200日簡單移動均線切入位在0.30加元。Alpha Cognition的52周低點為0.15加元,52周高位為1.08加元。
關於阿爾法認知
(獲取評級)
Alpha Cognition Inc是一家臨床階段的生物製藥公司,專注於開發阿爾茨海默病和肌萎縮側索硬化症(ALS)的治療方法。它開發了一種用於治療阿爾茨海默氏型痴呆症和輕度創傷性腦損傷的乙酰膽鹼酯酵素抑制劑Alpha-1062,以及用於治療ALS的基因療法Alpha-0602。
專題報道
- 這項具有巨大增長前景的小型技術正在接近買入點
- 不要追逐聯盟快遞更高,等待回調
- 防禦性科技投資組合的3只股票
- 從這3頭現金母牛身上榨取分紅
- 歐洲加息,美聯儲應該效仿嗎?
接受《阿爾法認知日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Alpha Cognition和相關公司的最新新聞和分析師評級的每日簡要摘要。